|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Toxicology |
a Department of Obstetrics and Gynecology, Clinic for Endocrinology, University Hospital, 8091 Zurich, Switzerland
b Department of Medicine, Center for Clinical Pharmacology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania 15224
| ABSTRACT |
|---|
|
|
|---|
and ß), but the modulatory effects of estradiol, but not EEs, on ET-1 synthesis were blocked by ICI-182 780 (1 µM), a pure ER antagonist. Our results provide evidence that estradiol inhibits ET-1 synthesis in oviduct cells via an ER-dependent mechanism, whereas, EEs induce ET-1 synthesis via an ER-independent mechanism. The contrasting effects of EEs on ET-1 synthesis suggests that EEs may act as endocrine modulators/disruptors and may have deleterious effects on the reproductive system by adversely influencing the biology and physiology of the oviduct.
environment, estradiol receptor, growth factors, oviduct, toxicology
| INTRODUCTION |
|---|
|
|
|---|
The oviduct physiology is regulated by ovarian hormones such as 17ß-estradiol, which indirectly influences oviduct function and the fertilization process by controlling the synthesis of autocrine/paracrine factors within the oviduct [6]. Estradiol induces the synthesis of leukemia inhibitory factor [7], which plays a key role in implantation. Endothelin (ET-1), a potent contracting factor, is synthesized by cultured bovine oviduct epithelial cells and is able to induce contraction of bovine oviduct segments [4, 8].
The biologic effects of estradiol are largely mediated via estrogen receptors (ER
and ERß); however, emerging evidence also supports nongenomic and non-receptor-mediated estradiol effects [9]. The endocrine effects of estradiol can be mimicked and blocked by several chemical agents that are structurally similar to estradiol, agents that bind to ERs or posses estrogenic activity. These estrogen like chemicals are termed environmental estrogens (EEs) and are classified into two major categories: phytoestrogens (plant-derived estrogens) and xenoestrogens (man-made estrogenic chemicals).
Environmental estrogens interfere with the reproductive process of humans and other species [9]. Although the deleterious effects of environmental estrogens on the reproductive system have been well established, the mechanisms involved remain undefined. The fact that some environmental estrogens induce estrogenic effects whereas others are antiestrogenic [9] has further complicated the issue. Moreover, recent studies have provided evidence that compared with estradiol many of the environmental estrogens known to act as endocrine disruptors have a very low binding affinity for ER
and ERß [9], suggesting that they may mediate their effects via alternative ER-independent mechanisms.
The aims of the present study were to determine whether 1) ET-1 synthesis by oviduct cells is regulated by estradiol, 2) phytoestrogens and xenoestrogens influence the synthesis of ET by oviduct cells, 3) oviduct cells express ER
and ERß, and 4) the effects of estradiol, phytoestrogens, and polychlorinated biphenyls (PCBs) on ET-1 synthesis are ER mediated. For the present study, we selected five major soya-derived phytoestrogens (genistein, daidzein, biochanin A, equol, and formononetin), one PCB (trichlorobiphenyl [TCB]), and two hydroxylated PCBs (4-hydroxy-dichlorobiphenyl [4-OH-DCB] and 4-hydroxy-trichlorobiphenyl [4-OH-TCB]), which have been identified in human and animal sera.
| MATERIALS AND METHODS |
|---|
|
|
|---|
Oviducts of young cyclic nonpregnant cows were obtained from the local abattoir, and oviduct cells (mixed population of epithelial cells and fibroblasts, 1:1 ratio) were cultured in Ham F10 (Sigma, Buchs, Switzerland) containing 10% fetal calf serum (FCS, steroid-free, one batch; Sigma) according to our previously published method [7]. Confluent monolayers of these mixed oviduct cells after 68 days in culture were used. These mixed cell cultures were characterized immunohistochemically as previously described [4, 7]. Monoclonal antibodies to epithelial cell cytokeratin (anticytokeratin AE1/AE3; DAKO Diagnostiks AG, Zug, Switzerland) and antibodies against fibroblast vimentin (antivimentin VIM 3B4; DAKO) were used to identify the epithelial cells and fibroblasts in culture. Peroxidase-antiperoxidase staining (DAKO) was used to visualize the antibody reactions.
ET-1 synthesis was investigated in primary cell cultures or cells in first passage. Oviduct epithelial cells synthesize ET-1 [4], and preliminary studies conducted with cultured oviduct fibroblasts demonstrated that these cells also synthesize ET-1 (117 ± 24 pg/mg protein after 4 days; P < 0.05 vs. Day 0). Because autocrine/paracrine factors generated by both epithelial cells and fibroblasts may regulate the physiology and biology of the oviduct, we used the coculture system to analyze the effects of natural and environmental estrogens on ET-1 synthesis. Using the same experimental model, we previously demonstrated that estradiol and EEs modulate the synthesis of leukemia inhibitory factor [7], and the effects were similar in epithelial cells, fibroblasts, and cocultured cell systems [10].
Treatment Protocols for ET-1 Synthesis
To study the effects of ovarian hormones on ET-1 synthesis in bovine oviduct cells, confluent monolayers of mixed cell cultures (epithelial cells and fibroblasts, 1:1) were washed twice with Hanks balanced salt solution and treated for 4 days with Dulbecco modified Eagle medium (DMEM)/Ham F12 medium (Gibco BRL, Life Technologies, Grand Island, NY) supplemented with 1% FCS (steroid free) and containing or lacking 17ß-estradiol (4, 40, 200, and 400 nM; Sigma). To evaluate whether the effects of 17ß-estradiol were ER mediated, cells were treated with 17ß-estradiol (0.2 µM) or genistein (0.2 µM; Extrasynthèse, Genay, France), an ERß ligand, with or without ICI 182,780 (1 µM; Tocris, Cookson Ltd., Bristol, U.K.), a specific ER antagonist. To investigate the influence of phytoestrogens and xenoestrogens on ET-1 synthesis, cells were incubated for 4 days with DMEM/Ham F12 medium with 1% FCS (steroid free) with or without various phytoestrogens (0.22 µM biochanin A, daidzein, equol, formononetin, and genistein; Extrasynthèse), or xenoestrogens (0.110 µM TCB, 4-OH-DCB, and 4-OH-TCB; AccuStandard, New Haven, CT). To evaluate whether the effects of EEs on ET-1 synthesis were ER mediated, the mixed cell cultures were treated for 4 days with TCB, 4-OH-TCB, and 4-OH-DCB (0.1 µM) with or without ICI 182,780 (1 µM).
Quantitative Analysis of ET-1
To analyze ET-1, the cell culture medium/supernatant was collected and microfuged. ET-1 levels in 100-µl aliquots of the supernatant were quantified using a highly sensitive ET-1 human ELISA kit (Biotrak; Amersham, Dubendorf, Switzerland), with the following specification: ET-1 sensitivity of 0.1 pg/ml; cross-reactivity with ET-2 (synthetic) of <1%, cross-reactivity with ET-3 (synthetic) of <0.001%, and very low cross-reactivity with big ET-1 (human and porcine) and sarafotoxin S6b. The inter- and intra-assay coefficients of variation were <10%. To verify that cytoplasmic proteins did not interfere with the assay, standard curves of ET-1 were run in culture medium with or without cytoplasmic extracts of oviduct cells (1 mg/ml; extracted from confluent monolayers of cells grown in 75-cm2 flasks) and spiked with 020 pg/ml of ET-1. The standard curves for ET-1 with or without cytoplasmic extracts and after subtracting the blanks did not vary significantly; the assay curves were linear and almost identical (Fig. 1). The concentrations of ET-1 were calculated using a standard curve run under identical conditions. ET-1 concentrations were normalized to total cell proteins and are presented as picograms per milligram protein. Confluent monolayers were used to rule out the contribution of change in cell number. Total cellular protein levels also were measured.
|
Protein Estimation
Cells remaining after the removal of the cell culture supernatant were solubilized in 0.1% SDS, and the total protein concentration was determined with the Bio-Rad Protein Assay (Bio-Rad, Glattbrugg, Switzerland) using BSA as the standard. Each experiment was conducted in triplicate and repeated three or four times using cell cultures form different pools of fresh oviducts.
ER Expression and Binding Studies
To investigate whether the oviduct cells express ER
and ERß, cell lysates from cultured oviduct cells were analyzed by Western blots and probed with antibodies to ER
(purified antiserum to human ER
; Alexis Corp., Lausen, Switzerland) and ERß (purified antiserum to human ER-ß; Alexis). Samples containing 25 µg protein were loaded on 10% SDS-polyacrylamide gels, and proteins were separated by electrophoresis. The proteins were transferred to nitrocellulose membranes (Schleicher and Schuell GmbH, Dassel, Germany) and blocked overnight with 5% milk proteins and 0.2% Tween-30 in PBS. The membranes were probed with antibodies to ER
(dilution 1:1000 in 1% milk protein and 0.2% Tween-20 in PBS) or ERß (dilution 1:1000) for 1 h. Subsequently, the membranes were washed and treated with a peroxidase-conjugated second antibody (goat anti-rabbit; Pierce, Lausanne, Switzerland). Membranes were then exposed to the substrate (Supersignal west Dura substrate; Pierce), and the labeled proteins were detected by exposing the x-ray films to the membranes.
Receptor binding studies were conducted to ascertain the binding affinity of estradiol to the oviduct cells and to obtain a quantitative estimate for the presence of ERs in oviduct cells. Confluent monolayers of oviduct cells in 35-mm2 culture dishes were treated with 0.58 x 10-9 M [3H]17ß-estradiol for 1 h at 37°C in serum-free medium. The labeled cytosol was subsequently extracted, and the free estrogen was removed by incubating the cytosol with dextran-coated charcoal. Total binding of [3H]17ß-estradiol was quantified by measuring the radioactivity in a liquid scintillation counter, as previously described [10]. Nonspecific binding was measured by parallel incubations in the presence of a 1000-fold excess of unlabeled 17ß-estradiol. Binding data was analyzed by nonlinear isotherm equation and by Scatchard analysis (GraphPad).
Statistical Analysis
Data are presented as mean ± SD. Statistical analysis by ANOVA was performed using the Statview program. For individual comparisons for significant differences, both the Fisher probable least significant difference (PLSD) test and the Student-Newman-Keuls posteriori test were performed. A P value of <0.05 was considered significant.
| RESULTS |
|---|
|
|
|---|
Detectable amounts of ET-1 were found in the supernatant of the primary cultures of mixed bovine oviduct cells (epithelial cells and fibroblasts) collected after 4 days of culture. ET-1 concentrations were 95150 pg/mg protein. In the cell cultures treated with 4, 40, 200, and 400 nM of 17ß-estradiol, the ET-1 levels decreased in a concentration-dependent manner from 142 ± 14 pg/mg protein (untreated control) to 108.4 ± 11.6, 99 ± 10.3, 80.25 ± 11, and 48.3 ± 8 pg/mg protein, respectively (Fig. 2, bottom). The decreases in ET-1 levels observed were not due to the effects of estradiol on cell growth because the total cellular protein content did not change (Fig. 2, top).
|
ICI 182,780 Modulates the Inhibitory Effects of 17ß-Estradiol on ET-1 Synthesis
To study the modulatory effects of ICI 182,780, cells were pretreated with ICI 182,780 (1 µM). The inhibitory effects of 17ß-estradiol (50 ng/ml, 0.2 µM) on ET-1 synthesis were completely reversed in the presence of ICI 182,780 (Fig. 3). Compared with the untreated controls, the ET-1 levels in cell cultures treated with 17ß-estradiol decreased from 130.6 ± 15 pg/mg protein to 84.14 ± 12.1 pg/mg protein, whereas in those cultures treated with 17ß-estradiol plus ICI 182,780 the ET-1 levels increased to 195 ± 37 pg/mg protein (P < 0.05 vs. control; Fig. 3). The inhibitory effects of near physiological concentrations of estradiol (4 nM) on ET-1 synthesis were also completely blocked by 1 µM ICI 182,780. The levels of ET-1 in untreated cells and cells treated with 4 nM estradiol and estradiol plus 1 µM ICI 182,780 were 130.6 ± 14.5, 101 ± 8 (P < 0.05 vs. control), and 129 ± 6 pg/mg protein, respectively (P < 0.05 vs. estradiol). The changes in ET-1 levels were not due to the effects of the modulatory agents on cell growth because the total cellular protein content did not change (Fig. 3, top).
|
Effects of Phytoestrogens and PCBs on ET-1 Synthesis
In contrast to the effects of 17ß-estradiol, ET-1 synthesis by oviduct cells was significantly induced in the presence of some but not all of the phytoestrogens. Significant increases in ET-1 levels were observed in cells treated with the phytoestrogens biochanin A and genistein. In cultures treated with 2 µM biochanin A and genistein, ET-1 synthesis was significantly increased from 139 ± 19 pg/mg protein to 305 ± 45 pg/mg protein (P < 0.05 vs. control) and 301.7 ± 43 pg/mg protein (P < 0.05 vs. control), respectively (Fig. 4, bottom). In cells treated with 2 µM formononetin, equol, and daidzein, ET-1 levels were not significantly increased, from 139 ± 19 pg/mg protein to 198 ± 68, 192 ± 85.2, and 15 8 ± 55 pg/mg protein (P > 0.05 vs. control), respectively. The changes in ET-1 levels were not due to the effects of the modulatory agents on cell growth because the total cellular protein content did not change (Fig. 4, top).
|
Similarly, ET-1 synthesis was also significantly stimulated in bovine oviduct cells treated with the xenoestrogens TCB (0.110 µM), 4-OH-TCB (0.110 µM), and 4-OH-DCB (0.110 µM). The lowest concentrations of TCB, 4-OH-DCB, and 4-OH-TCB that significantly induced ET-1 synthesis were 10 µM, 0.1 µM, and 0.1µM, respectively. Stimulatory effects of TCB on ET-1 synthesis were observed at 10 µM but not at lower concentrations of 0.1 and 1 µM (Fig. 5, bottom). Compared with the untreated controls, ET-1 increased from 137 ± 23 pg/mg protein to 218 ± 38 pg/mg protein in cells treated with 10 µM TCB (P < 0.05), 334 ± 60 pg/mg protein in cells treated with 0.1 µM 4-OH-TCB (P < 0.05), and 233 ± 41 pg/mg protein in cells treated with 0.1 µM 4-OH-DCB (P < 0.05; Fig. 5, bottom). The stimulatory effects of 4-OH-TCB and 4-OH-DCB were more potent than that of TCB. The changes in ET-1 levels were not due to the effects of the modulatory agents on cell growth because the total cellular protein content did not change (Fig. 5, top).
|
ICI 182,780 Modulates Phytoestrogen- and PCB-Induced ET-1 Synthesis
The stimulatory effects of biochanin A (0.2 µM) and genistein (2 µM) on ET-1 synthesis were differentially modulated by ICI 182,780 (1 µM). In the presence of ICI 182,780 the stimulatory effects of biochanin A on ET-1 synthesis were decreased from 436 ± 78 to 334 ± 108 pg/mg protein and the stimulatory effects of genistein on ET-1 synthesis were increased from 299 ± 30.3 to 351 ± 47 pg/mg protein (Fig. 6, bottom). The changes in ET-1 levels were not due to the effects of the modulatory agents on cell growth because the total cellular protein content did not change (Fig. 6, top).
|
In the presence of ICI 182,780, the stimulatory effect of 0.1 µM 4-OH-TCB was reduced from 334 ± 74 to 203 ± 47 pg/mg protein (P < 0.05) and the effects of 0.1 µM 4-OH-DCB were increased from 233 ± 53 to 330 ± 17.4 pg/mg protein (P < 0.05). ICI 182,780 also increased the stimulatory effects of TCB (0.1 µM) on ET-1 synthesis from 190.5 ± 28.5 to 274 ± 71 pg/mg protein (P < 0.05; Fig. 7, bottom). The changes in ET-1 levels were not due to the effects of the modulatory agents on cell growth because the total cellular protein content did not change (Fig. 7, top).
|
ER
and ERß Expression and Binding Studies
Western blot analysis of oviduct cell lysates showed that both ER
and ERß are highly expressed in the oviduct cells (Fig. 8). Binding studies revealed that [3H]17ß-estradiol binds with high affinity and specificity to ERs in oviduct cells. The binding isotherm showed a saturable binding process, and the Scatchard analysis revealed that the number of binding sites ranged between 16.5 and 19 fmol/mg protein (Fig. 8, B and C) with a dissociation constant (Kd) of 3.58 ± 0.7 nM.
|
| DISCUSSION |
|---|
|
|
|---|
In the oviduct, the synchronized processes of fertilization, embryo transport, and implantation are controlled by the cyclic release of sex hormones such as estradiol [6]. Therefore, the influence of estradiol on ET-1 synthesis may be of physiological and biological relevance. In this context, the local release of ET in the oviduct may be involved in the cyclic contractions regulated by ovarian hormones. Treatment of uterine segments in vitro with hormones reduces ET-induced contractions [12]. In bovine endothelial cells, ET-1 synthesis is attenuated by estradiol [13, 14].
In the present study, a mixed culture system of oviduct epithelial and fibroblast cells was used to evaluate the effects of estradiol and EEs to reflect in vivo physiology. In the female reproductive tract, ERs are located in the stroma cells [15, 16], and interactions between epithelial cells and fibroblasts play an important role in maintaining oviductal biology and physiology. Factors synthesized by fibroblasts influence epithelial cell function in an autocrine/paracrine fashion in the female reproductive tract [17].
Basal synthesis of ET-1 by oviduct cells was inhibited by estradiol. Similar inhibitory effects of estradiol on ET-1 synthesis have been observed in vascular endothelial cells [14]. Our observations that the oviduct cells express both ER
and ERß and that the inhibitory effects of estradiol were completely reversed in the presence of the ER antagonist ICI 182,780 (which binds with equal affinity to ER
and ERß) provide direct evidence that the inhibitory effects were ER mediated. However, the individual roles of ER
and ERß in mediating the inhibitory effects of estradiol are still unclear. In contrast to estradiol, genistein, a phytoestrogen with high affinity for ERß (98% binding affinity for ERß and 4% binding affinity for ER
[11]), did not inhibit ET-1 synthesis. This finding suggests that the inhibitory effects of estradiol on ET-1 synthesis are potentially ER
mediated. This notion is further supported by the fact that the modulatory effects of estradiol, but not genistein, were blocked by ICI 182,780.
In the presence of ICI 182,780, the inhibitory effects of estradiol on ET-1 synthesis were not blocked but were stimulated. This finding implies that the oviduct cells may synthesize endogenous estrogens or estradiollike molecules that inhibit ET-1 synthesis via ERs. Basal synthesis of ET-1 was consistently increased by 2030% in oviduct cells treated with ICI 182,780, although this increase did not reach statistical significance. Aromatase, a key enzyme in the synthesis of estradiol, is present in multiple tissues, including the oviduct [18]. Thus, local synthesis of estradiol or estradiollike molecules is plausible and may negatively regulate ET-1 synthesis via ER-dependent mechanisms. Alternatively, factors in 1% FCS (charcol stripped, hormone free) used in this study may have stimulated ET-1 synthesis via ERs, and this effect would be blocked by ICI 182,780. Growth factors induce the estrogen response element [19], which mediates most of the ER-mediated effects.
In contrast to estradiol, phytoestrogens induced ET-1 synthesis in oviduct cells, and these effects were not positively correlated with their binding affinity to ERs, suggesting that these stimulatory effects were mediated via ER-independent mechanisms. Biochanin A, a precursor of genistein with 10 000 fold less binding affinity for both ER
and ERß [11], was more potent than genistein, a ERß ligand, in inducing ET-1 synthesis. This finding further supports the hypothesis that phytoestrogens mediate their stimulatory effects on ET-1 synthesis via some ER-independent mechanism. Similar to phytoestrogens and in contrast to estradiol, the PCBs TCB, 4-OH-TCB, and 4-OH-DCB induced ET-1 synthesis in oviduct cells. Again, the potency of the PCBs in inducing ET-1 synthesis was not correlated with their binding affinity to ERs. The stimulatory effects of PCBs were not blocked by ER antagonist ICI 182,780, suggesting that the stimulatory effects were mediated via an ER-independent mechanism(s). In this context, xenoestrogens and phytoestrogens bind to arylhydrocarbon (Ah) receptors, and these receptors play a critical role mediating the antiestrogenic effects of EEs by modulating their metabolism [9, 19]. Therefore, we hypothesize that the stimulatory effects of EEs on ET-1 synthesis are Ah receptor mediated; however, this possibility needs to be explored.
Apart from the Ah receptor, other mechanisms may also be involved in mediating the stimulatory effects of EEs on ET-1 synthesis. PCBs stimulate the release of free radicals [9], which are known to stimulate ET-1 synthesis. PCBs also inhibit the free radical scavenging systems, i.e., superoxide dismutase and reduced glutathione [9], which may further potentiate the effects of free radicals on ET-1 synthesis. Phytoestrogens are known to bind to a newly identified functional type II ER [9], which regulates cell growth and function, and may be responsible for mediating its stimulatory effects on ET-1 synthesis. Studies are needed to elucidate the exact mechanism(s) involved in these actions.
The lowest concentrations of PCBs and phytoestrogens that induced ET-1 synthesis were 0.1 µM and 0.2 µM, respectively. At a similar concentration, i.e., 0.2 µM, the inhibitory effects of estradiol on ET-1 synthesis were much lower than the stimulatory effects of EEs on ET-1 synthesis. PCBs accumulate in the body to a greater extent and so may have a stronger impact on the reproductive system. PCBs are relatively new, synthetic estrogens, whereas consumption of phytoestrogens has coevolved with hormonal regulation of the reproductive system. Under in vivo situations, the total plasma concentrations of phytoestrogens (equol, daidzein, formononetin, genistein, biochanin A) in humans consuming a soya-rich diet is 1.8 µM [9, 20]. However, on a normal/low-soya diet phytoestrogen concentrations may be relatively low. Because high concentrations of phytoestrogens and EEs are associated with reproductive disorders, continuous exposure to EEs and the presence of EEs within the body may result in increased ET-1 synthesis and may interfere with the cyclic, time-dependent physiological regulation of the oviduct, a key organ for reproductive processes. Because estradiol and phytoestrogens bind to ERs but have contrasting effects on ET-1 synthesis, presence of these EEs may block the effects of estradiol by competing for the ER.
In a previous study, we provided the first evidence that phytoestrogens and xenoestrogens mimic the effects of estradiol in inducing the synthesis of leukemia inhibitory factor by oviduct cells. We also provided evidence that these effects were mediated via an ER-dependent mechanism(s) [20] and potentially via ERß because genistein, an ERß ligand, induced leukemia inhibitory factor synthesis. In contrast to our previous findings, in the present study phytoestrogens and xenoestrogens did not mimic the effects of estradiol on ET-1 synthesis but rather had contrasting effects. Taken together these results suggest that EEs can modulate the synthesis of autocrine/paracrine factors via multiple mechanisms and via ER-dependent and ER-independent mechanisms. These effects could be estrogenic or antiestrogenic. Future studies are required to elucidate the various mechanisms by which EEs may directly or indirectly influence the reproductive system.
These findings provide the first evidence that ET-1 synthesis in oviduct cells is regulated by the ovarian hormone estradiol. The inhibitory effect of estradiol on ET-1 synthesis is ER mediated. EEs (phytoestrogens and xenoestrogens) do not mimic the inhibitory effects of estradiol on ET-1 synthesis but rather stimulate ET-1 synthesis, and these stimulatory effects on ET-1 synthesis are potentially mediated via an ER-independent mechanism. These contrasting effects of EEs on ET-1 synthesis may interfere with estradiol-mediated processes and may act as endocrine disrupters, possibly inducing deleterious effects on the reproductive system by influencing the biology and physiology of the oviduct and potentially leading to infertility.
| FOOTNOTES |
|---|
2 Correspondence. FAX: 41 1 255 44 39; marinella.rosselli{at}fhk.usz.ch ![]()
Received: 17 April 2002.
First decision: 28 May 2002.
Accepted: 1 November 2002.
| REFERENCES |
|---|
|
|
|---|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |